GLP-1 side effects: what’s normal and what’s not

Starting a GLP-1 medication like Wegovy (semaglutide) or Zepbound (tirzepatide) is a major step toward better health — and it is completely normal to wonder what to expect along the way. Side effects are a common part of the treatment process, especially during the early weeks and during dose increases. The key is knowing which side effects are routine and which ones need clinical attention.

This guide walks you through the most frequently reported side effects, explains what is considered normal during titration, and outlines the warning signs that should prompt a call to your provider. If you are a current or prospective PEAK patient, this is the information your care team wants you to have.

Common GI side effects

GLP-1 receptor agonists work by slowing gastric emptying and signaling fullness to the brain. These mechanisms are responsible for the appetite suppression that drives weight loss — but they also explain why the most common side effects involve the digestive system.

The four most frequently reported gastrointestinal side effects are:

• Nausea. The most common side effect overall. Most patients experience mild to moderate nausea during the first 1–2 weeks of a new dose. It typically improves as your body adjusts. Eating smaller meals, avoiding greasy foods, and staying hydrated can help significantly.
• Constipation. Slower gastric motility can reduce bowel movement frequency. Increasing fiber intake, drinking plenty of water, and staying physically active are the first-line remedies. If constipation persists, your clinician may recommend an over-the-counter option.
• Diarrhea. Less common than nausea or constipation, but reported by some patients — particularly in the early weeks. It usually resolves without intervention. Persistent diarrhea warrants a check-in with your provider.
• Vomiting. Occasional vomiting can occur, especially if you eat too quickly or consume large portions while your gastric emptying is slowed. Frequent or severe vomiting is not normal and should be reported immediately.

Normal vs. concerning

Understanding the difference between expected adjustment symptoms and red flags is one of the most important things you can do as a patient. Here is how to think about it:

What is normal during titration

• Mild nausea that comes and goes, especially in the first 3–5 days after a dose increase
• Reduced appetite — this is the medication working as intended
• Occasional loose stools or minor constipation
• Mild fatigue or low energy as your caloric intake decreases
• Slight bloating or feeling full faster than usual

These effects are typically self-limiting. They tend to peak in the first week of a new dose and resolve within 2–3 weeks. If they persist beyond a full titration cycle, your clinician can adjust your plan — sometimes by extending the time at a given dose before moving up.

What warrants a call to your provider

• Nausea or vomiting that prevents you from eating or drinking for more than 24 hours
• Significant dehydration symptoms: dark urine, dizziness, rapid heartbeat
• Abdominal pain that is sharp, severe, or worsening
• Side effects that do not improve at all after 3–4 weeks on the same dose
• Any new symptom that feels different from your typical GI adjustment pattern

Serious warning signs

Serious adverse events on GLP-1 medications are rare, but they do exist. Every patient should be aware of the following warning signs, which require prompt medical evaluation:

Other less common but reportable concerns include gallbladder issues (right upper abdominal pain, especially after fatty meals), signs of hypoglycemia if you are on concurrent diabetes medications, and kidney problems indicated by changes in urination or swelling in the legs.

Wegovy vs. Zepbound: side effect differences

Both Wegovy (semaglutide) and Zepbound (tirzepatide) are GLP-1 receptor agonists, but they are not identical. Zepbound also activates the GIP receptor, which gives it a dual mechanism of action. This difference can affect the side-effect experience:

• Nausea. Wegovy tends to produce more nausea, particularly at higher maintenance doses. Many patients and clinicians report that Zepbound’s nausea is less persistent, though it still occurs during titration.
• Diarrhea. Zepbound may cause slightly more diarrhea compared to Wegovy, particularly in the early dose stages.
• Constipation. Reported at similar rates for both medications.
• Injection site reactions. Both can cause mild redness, itching, or swelling at the injection site. These are typically minor and resolve within a day or two.

Managing common side effects

Most GLP-1 side effects can be managed with simple, practical strategies. Here are the approaches that our clinical team recommends most often:

• Eat smaller, more frequent meals. Instead of three large meals, try five or six smaller portions throughout the day. This reduces the burden on a stomach that is emptying more slowly.
• Avoid trigger foods. Greasy, fried, and heavily spiced foods are the most common triggers for nausea and GI discomfort. Bland, protein-rich foods are usually better tolerated.
• Stay hydrated. Drink water consistently throughout the day. Dehydration worsens nausea and constipation. If plain water is unappealing, try adding a squeeze of lemon or sipping on clear broths.
• Increase fiber gradually. For constipation, add fiber slowly to avoid bloating. Vegetables, whole grains, and a fiber supplement like psyllium husk can help.
• Time your injection strategically. Some patients find that injecting in the evening reduces daytime nausea. Others prefer mornings. Experiment to find what works for your body.

How PEAK monitors you through each dose increase

At PEAK, we do not prescribe a GLP-1 medication and ask you to figure it out on your own. Every patient receives structured clinical monitoring throughout the titration process and beyond. Here is what that looks like:

• Pre-treatment baseline. Before your first injection, we review your medical history, run baseline labs, and discuss what to expect. You leave your first appointment knowing exactly how to manage the most common side effects.
• Regular check-ins during titration. As you move through each dose level, your clinician checks in to evaluate how you are tolerating the medication. If side effects are problematic, we adjust — extending the time at a dose, adding supportive measures, or exploring a medication switch.
• Lab monitoring. We track metabolic markers, kidney function, and nutritional status at regular intervals. This allows us to catch issues before they become symptoms.
• Dietitian support. Your nutrition plan is designed to minimize side effects. The right foods at the right times can make a significant difference in how you feel during treatment.

Why in-person monitoring matters

Telehealth GLP-1 prescribers have made these medications more accessible, and that is a positive development. However, there are real limitations to managing side effects remotely — particularly for patients who are new to these medications or who have complex medical histories.

In-person visits allow your clinician to:

• Perform a physical examination. Abdominal tenderness, injection site reactions, thyroid changes, and signs of dehydration are best assessed in person.
• Draw labs on the spot. If something does not seem right, we can run bloodwork the same day rather than coordinating external lab visits.
• Read body language and context. Patients often underreport symptoms in a chat or questionnaire. Face-to-face conversation catches nuances that digital forms miss.
• Make real-time adjustments. If a dose change or supportive medication is needed, it happens during your visit — not days later after an email chain.

Side effects are a manageable part of GLP-1 treatment, not a reason to avoid it or stop it prematurely. With the right clinical support, most patients move through the titration period with minimal disruption to their daily lives. The long-term health benefits — sustained weight loss, improved metabolic markers, reduced cardiovascular risk — far outweigh a few weeks of adjustment.

At PEAK, we are here for every dose increase, every question, and every concern. That is what complete care looks like.

Medication labeling reminder: Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes only. For weight management, the FDA-approved options are Wegovy (semaglutide) and Zepbound (tirzepatide).

Boxed warning — thyroid C-cell tumors: GLP-1-based medications (including semaglutide and tirzepatide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. These medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.

The PEAK Clinical Team

PEAK Wellness & Aesthetics

Evidence-based guidance from our board-certified clinicians specializing in medical weight loss and obesity medicine.